Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab combination umbrella study in advanced non-small cell lung cancer
NL-OMON50768Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sasanlimab, encorafenib, binimetinib, axitinib and SEA-TGT in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities, Durable objective response and 1 more. Planned start Jan 2022; status: withdrawn.
02
Drugs
sasanlimabencorafenibbinimetinibaxitinibSEA-TGT
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50768.